Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
Theramex is a global pharmaceutical company specialising in women's health products, such as hormone replacement therapy (HRT) and fertility treatments.
During its initial Phase 1 review, the CMA identified that Theramex is one of the largest suppliers in the systemic HRT market in the
The CMA is concerned that the deal could reduce competition in this important market, the cost of which is often covered by the
The CMA has also identified concerns that the merger could also lead to a loss of future competition on the
HRT plays a critical role in treating symptoms which impact the everyday lives of millions of women.
We're concerned this deal between Theramex and
Our door is now open to the firms to offer solutions to our concerns, otherwise this case will proceed to a more in-depth investigation.
Both Theramex and
More information can be found on the Theramex /
Notes to editors:
1 Theramex is headquartered in the
2 Phase 2 investigations last 24 weeks (extendable by up to 8 weeks in certain circumstances) and are led by an independent panel of experts.
3 For media enquiries, contact the CMA press office on 020 3738 6460 or press@cma.gov.uk.
.
(C) 2024 M2 COMMUNICATIONS, source